摘要:
Novel β-aryl-α-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.
摘要:
An energy storage device includes a cathodic material in an activated state; and an anodic material in an activated state; wherein: the cathodic material is a viologen covalently attached to, or confined within, a first polymer matrix, the first polymer matrix is configured to prevent or minimize substantial diffusion of the cathodic material in the activated state; and the anodic material is a phenazine, a phenothiazine, a triphenodithiazine, a carbazole, a indolocarbazole, a biscarbazole, or a ferrocene covalently attached to, or confined within, a second polymer matrix, the second polymer matrix is configured to prevent or minimize substantial diffusion of the anodic material in the activated state.
摘要:
Die Erfindung betrifft ein Verfahren zur Diagnose oder Prädiagnose einer β-Amyloidopathie oder α-Synucleopathie, welche mit einer zerebralen Proteinablagerung und einer verminderten Aktivität des zerebralen ABCC1-Transporters einhergehen oder zur Ermittlung des Risikos eines Probanden, an einer solchen Krankheit zu erkranken, wobei der Proband bereits Substanzen zu sich nimmt, welche über den zerebralen ABCC1-Transporter transportiert werden.
摘要翻译:要求保护使用取代的10-(3-哌嗪-1-基 - 丙基)-10H-吩噻嗪-2-硫醇化合物(I)来治疗神经变性疾病。 要求使用式(I)的取代的10-(3-哌嗪-1-基 - 丙基)-10H-吩噻嗪-2-硫醇化合物治疗神经变性疾病。 R1,R2:1-6C-烷基(任选被烷基(任选被至少一个另外的卤原子取代),芳基,酰基,乙酰基,氨基,硝基,磺酰基,羟基,烷氧基,芳氧基,芳硫基,烷硫基或卤素取代) ; R 3:H,烷基(任选被至少一个另外的卤原子取代),芳基,酰基,乙酰基,氨基,硝基,磺酰基,羟基,烷氧基,芳氧基,芳硫基,烷硫基,卤素,NR 4 R 5 - 或OR 6; R4-R6:H或1-3C-烷基; R 7:H,烷基(任选被至少一个另外的卤原子取代),芳基,酰基,乙酰基,氨基,硝基,磺酰基,羟基,烷氧基,芳氧基,芳硫基,烷硫基,卤素,NR 8 R 9或OR 10; 和R 8 -R 10:H或1-3C-烷基。 活动:神经保护; 精神药物; 镇惊; 抗帕金森氏病; 脑保护; 催眠; 抗炎。 行动机制:无给予。
摘要:
The invention relates to 2-(R 2 -thio)-10-[3-(4-R 1 -piperazin-1-yl)propyl]-10 H -phenothiazine according to general formula I, for treating a β-amyloidopathy or an α-synucleinopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter. The invention also relates to a method for the diagnosis or prediagnosis of a β-amyloidopathy or an α-synucleopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter, or for determining the risk of a proband suffering from such an illness, the proband already having accumulated substances transported by the cerebral ABCC1 transporter.
摘要:
The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.